Nanotechnology for Alzheimer Disease.

Area of Science:

• Neuroscience
• Biotechnology
• Materials Science

Background:

• Alzheimer disease (AD) impacts behavior, memory, and cognition.
• Brain changes in AD begin 10-20 years before symptom onset.
• Early diagnosis and treatment of AD are hindered by a lack of validated biomarkers.

Purpose of the Study:

• To review current challenges in Alzheimer disease diagnosis and therapy.
• To emphasize the potential of biocompatible nanoparticles (NPs) in addressing these challenges.

Main Methods:

• Nanoparticles (NPs) in the 1-100 nm range can cross the blood-brain barrier.
• Biocompatible nanomaterials with magnetic and optical properties are explored.
• Targeted drug delivery systems using NPs are investigated.

Main Results:

• Nanotechnology offers effective diagnostic and therapeutic options for AD.
• NPs can facilitate targeted drug delivery (e.g., Rivastigmine) with reduced side effects.
• Nanomaterials show potential as early diagnostic agents due to enhanced magnetic and optical properties.

Conclusions:

• Nanoparticle-based approaches hold significant promise for breakthroughs in early AD diagnosis and therapy.
• Biocompatible NPs can serve as effective imaging contrast agents and drug carriers for CNS disorders.
• Continued research in NP-based drug delivery is crucial for advancing AD management.